203 related articles for article (PubMed ID: 33682111)
1. The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
Tharakan S; Zhong X; Galsky MD
Cancer; 2021 Jul; 127(13):2294-2301. PubMed ID: 33682111
[TBL] [Abstract][Full Text] [Related]
2. Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.
Dymanus KA; Butaney M; Magee DE; Hird AE; Luckenbaugh AN; Ma MW; Hall ME; Huelster HL; Laviana AA; Davis NB; Terris MK; Klaassen Z; Wallis CJD
Cancer; 2021 Sep; 127(17):3156-3162. PubMed ID: 34160824
[TBL] [Abstract][Full Text] [Related]
3. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
4. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
5. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
6. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
7. Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019.
Ajewole VB; Akindele O; Abajue U; Ndulue O; Marshall JJ; Mossi YT
JCO Oncol Pract; 2021 May; 17(5):e623-e628. PubMed ID: 33974825
[TBL] [Abstract][Full Text] [Related]
8. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
9. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
Xie Y; Liu Y; Qin Y; Chen X; Xie Q
Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
[TBL] [Abstract][Full Text] [Related]
11. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies.
Fatoki RA; Koehn K; Kelkar A; Al Hadidi S; Mehra N; Mian H; Landgren O; Kazandjian D; Hoffman J; Sborov DW; Mohyuddin GR
JCO Glob Oncol; 2022 Aug; 8():e2200119. PubMed ID: 35960904
[TBL] [Abstract][Full Text] [Related]
12. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
14. Minority Enrollment to Clinical Trials: Road to Increased Access.
Vose J
Oncology (Williston Park); 2021 Mar; 35(3):107. PubMed ID: 33818053
[TBL] [Abstract][Full Text] [Related]
15. Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Murthy VH; Krumholz HM; Gross CP
JAMA; 2004 Jun; 291(22):2720-6. PubMed ID: 15187053
[TBL] [Abstract][Full Text] [Related]
16. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
Awan FA; Becker AB; Wang Y; Kimmelman J
Ann Intern Med; 2022 Dec; 175(12):1675-1684. PubMed ID: 36410007
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
Allison K; Patel DG; Greene L
JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
[TBL] [Abstract][Full Text] [Related]
18. Demographic Disparities in the Federal Drug Approval Process for Allergic Rhinitis Medications.
Liebowitz A; Spielman DB; Schlosser RJ; Stewart MG; Gudis DA
Laryngoscope; 2023 Apr; 133(4):755-763. PubMed ID: 35394648
[TBL] [Abstract][Full Text] [Related]
19. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
Idris MY; Fitzsimmons WE; Pemu P
Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
